Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Grows By 1,543.6%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 281,382 shares, an increase of 1,543.6% from the May 31st total of 17,120 shares. Based on an average daily trading volume, of 2,102,038 shares, the short-interest ratio is currently 0.1 days. Currently, 6.4% of the company’s stock are short sold.

Institutional Trading of Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned about 1.28% of Galmed Pharmaceuticals at the end of the most recent reporting period. 76.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Galmed Pharmaceuticals Stock Down 3.4%

Shares of NASDAQ GLMD traded down $0.02 during trading hours on Friday, hitting $0.55. The company had a trading volume of 109,980 shares, compared to its average volume of 1,288,759. Galmed Pharmaceuticals has a 1-year low of $0.41 and a 1-year high of $2.34. The firm’s 50 day moving average is $0.62 and its 200-day moving average is $0.69. The stock has a market capitalization of $3.04 million, a P/E ratio of -0.45 and a beta of 0.73.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.